# Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

> **NCT04518501** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xing Xie** · enrollment: 50 (estimated)

## Conditions studied

- Efficacy and Safety

## Interventions

- **DRUG:** Arsenic trioxide Tablet +Fuzuloparib Capsules

## Key facts

- **NCT ID:** NCT04518501
- **Lead sponsor:** Xing Xie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2024-12-03
- **Final completion:** 2025-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518501, "Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04518501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*